The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AXOGEN INC | COM | 05463X106 | 30,326 | 2,429,999 | SH | SOLE | 2,429,999 | 0 | 0 | ||
CATALYST BIOSCIENCES INC | COM NEW | 14888D208 | 386 | 78,622 | SH | SOLE | 78,622 | 0 | 0 | ||
ENDOLOGIX INC | COM NEW | 29266S304 | 998 | 125,747 | SH | SOLE | 125,747 | 0 | 0 | ||
EYEPOINT PHARMACEUTICALS INC | COM | 30233G100 | 75,856 | 41,909,219 | SH | SOLE | 41,909,219 | 0 | 0 | ||
MEDICINOVA INC | COM NEW | 58468P206 | 9,539 | 1,170,370 | SH | SOLE | 1,170,370 | 0 | 0 | ||
REVANCE THERAPEUTICS INC | COM | 761330109 | 43,447 | 3,342,047 | SH | SOLE | 3,342,047 | 0 | 0 |